Spots Global Cancer Trial Database for Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Official Title: A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer
Study ID: NCT00074867
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer for patients who have failed first line platinum-based therapy and have a persistent rising CA-125.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Los Angeles, California, United States
Pfizer Investigational Site, Santa Monica, California, United States
Pfizer Investigational Site, Baltimore, Maryland, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, Boston, Massachusetts, United States
Pfizer Investigational Site, New York, New York, United States
Pfizer Investigational Site, Hamilton, Ontario, Canada
Pfizer Investigational Site, Quebec, , Canada
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
